BRIEF: Hengrui Pharma to raise up to $1.3 billion in Hong Kong IPO
Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) launched its Hong Kong IPO on Thursday, aiming to sell 225 million shares at a price range of HK$41.45 to HK$44.05 per share,…
BRIEF: Duality Biotherapies surges in Hong Kong trading debut
Shares of biotech firm Duality Biotherapeutics Inc. (9606.HK) opened up 91% at HK$181 on Tuesday and continued to climb in their Hong Kong trading debut, closing up 127% at HK$214.80…
Neautus looks outward to boost its traditional medicine story
The maker of traditional Chinese medicines has applied for a Hong Kong IPO after abandoning two listing attempts on China’s domestic A-share market Key Takeaways: Neautus has applied to list…
BRIEF: WuXi XDC’s revenue, profit jump in 2024
WuXi XDC Cayman Inc. (2268.HK), a provider of contract services for drug companies, said on Wednesday its revenue and profit rose sharply last year on strong demand for services related…
BRIEF: Wai Yuen Tong profit rises six-fold on non-operational gains
Drug and healthcare products maker Wai Yuen Tong Medicine Holdings Ltd. (0897.HK) announced on Wednesday its revenue fell 5.8% year-on-year to HK$347 million ($45 million) in the six months to…
NEWS WRAP: AstraZeneca China president assisting in investigation
The British drugmaker said Leon Wang is currently cooperating with an ongoing probe, as media reported the case involved the defrauding of China’s national insurance fund By A. Au…
BRIEF: BeiGene executive reportedly detained in AstraZeneca investigation
Yin Min, chief business officer for Greater China at innovative drugmaker BeiGene Ltd. (BGNE.US; 6160.HK; 688235.SH), has been detained as part of an investigation unrelated to the company’s operations, according…
Recent Articles
RELATED ARTICLES
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
BRIEF: Sany Heavy plans Hong Kong listing to raise up to $1.5 billion
600031.SHG
- BRIEF: Minieye IPO to raise up to $100 million in Hong Kong IPO
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
BRIEF: Guming to raise $220 million in Hong Kong IPO
1364.HK
-
BRIEF: CATL targets $4 billion in Hong Kong IPO, poised to become year’s top listing
300750.SHE
